{"id":"aromatase-inhibitor-and-growth-hormone","safety":{"commonSideEffects":[{"rate":null,"effect":"Gynecomastia (reduced by aromatase inhibition)"},{"rate":null,"effect":"Injection site reactions (growth hormone)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Fluid retention"}]},"_chembl":{"chemblId":"CHEMBL2108078","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aromatase inhibitors block the conversion of androgens to estrogen, which can help delay epiphyseal closure and extend the growth window in children with growth disorders. Concurrent growth hormone supplementation directly stimulates linear growth through IGF-1 signaling and anabolic effects on bone and muscle tissue. Together, these agents aim to maximize final adult height in growth-hormone-deficient or growth-restricted pediatric populations.","oneSentence":"This combination therapy inhibits aromatase to reduce estrogen production while supplementing growth hormone to promote linear growth in pediatric patients.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:29.187Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency in children"},{"name":"Short stature in pediatric patients"}]},"trialDetails":[{"nctId":"NCT06843967","phase":"PHASE1, PHASE2","title":"A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-19","conditions":"Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma","enrollment":54},{"nctId":"NCT04498481","phase":"","title":"TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-01","conditions":"Breast Cancer","enrollment":1},{"nctId":"NCT04305496","phase":"PHASE3","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-04-16","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":818},{"nctId":"NCT07366632","phase":"PHASE1","title":"A Study of Single Dose of BL0175 in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-01-26","conditions":"Postmenopausal Women","enrollment":27},{"nctId":"NCT06086340","phase":"","title":"Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-09-29","conditions":"Breast Cancer","enrollment":779},{"nctId":"NCT06139107","phase":"PHASE1","title":"RADIANT: Pre-op Radiation With Abemaciclib and Letrozole","status":"RECRUITING","sponsor":"Mridula George, MD","startDate":"2024-08-22","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT03822468","phase":"PHASE2","title":"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-11","conditions":"Breast Cancer","enrollment":376},{"nctId":"NCT03959891","phase":"PHASE1","title":"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-05-30","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT04227327","phase":"PHASE2","title":"Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)","status":"TERMINATED","sponsor":"University of Milano Bicocca","startDate":"2020-01-07","conditions":"Advanced Breast Cancer","enrollment":31},{"nctId":"NCT06307457","phase":"","title":"A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-03-06","conditions":"Breast Cancer","enrollment":604},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT06996093","phase":"PHASE3","title":"Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-02","conditions":"Breast Cancer","enrollment":2508},{"nctId":"NCT03219476","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-02-05","conditions":"Breast Cancer, Invasive Breast Cancer","enrollment":37},{"nctId":"NCT05304962","phase":"PHASE1","title":"FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Regor Pharmaceuticals Inc.","startDate":"2022-03-04","conditions":"Breast Cancer","enrollment":64},{"nctId":"NCT06702618","phase":"PHASE2","title":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-01","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT05584644","phase":"","title":"A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-24","conditions":"Breast Cancer, Breast Carcinoma, Breast Neoplasms","enrollment":150},{"nctId":"NCT04707196","phase":"PHASE4","title":"A Study of Abemaciclib in Indian Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":200},{"nctId":"NCT04916509","phase":"","title":"Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-13","conditions":"Breast Neoplasms","enrollment":258},{"nctId":"NCT05135104","phase":"","title":"Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period","status":"UNKNOWN","sponsor":"Asociatia Oncohelp - Centrul de Oncologie Oncohelp","startDate":"2021-12-15","conditions":"Metastatic Breast Cancer","enrollment":650},{"nctId":"NCT05800197","phase":"","title":"Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2014-04-15","conditions":"Breast Cancer, Neoadjuvant Endocrine Therapy","enrollment":300},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT04047758","phase":"PHASE3","title":"Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2019-09-01","conditions":"Breast Cancer","enrollment":420},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT01491737","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02-17","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT03846583","phase":"PHASE1","title":"Tucatinib + Abemaciclib + Herceptin for HER2+ MBC","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-06-28","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT03988114","phase":"PHASE4","title":"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2019-09-16","conditions":"Metastatic Breast Cancer","enrollment":""},{"nctId":"NCT02970682","phase":"PHASE2","title":"SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Evgen Pharma","startDate":"2016-10","conditions":"Breast Neoplasm","enrollment":60},{"nctId":"NCT01248416","phase":"PHASE3","title":"Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2010-11","conditions":"Idiopathic Short Stature","enrollment":76},{"nctId":"NCT00516698","phase":"","title":"Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2007-09","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT02530411","phase":"PHASE2","title":"Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer","status":"UNKNOWN","sponsor":"Velindre NHS Trust","startDate":"2015-04","conditions":"Neoplasms","enrollment":160},{"nctId":"NCT00119262","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-10","conditions":"Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer","enrollment":226},{"nctId":"NCT00945360","phase":"PHASE1","title":"Aromatase Inhibitors for Treatment of Uterine Leiomyomas","status":"WITHDRAWN","sponsor":"American University of Beirut Medical Center","startDate":"2011-03","conditions":"Symptomatic or Large Uterine Fibroids","enrollment":""},{"nctId":"NCT00133354","phase":"PHASE2, PHASE3","title":"Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2001-11","conditions":"Hypopituitarism","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arimidex (Anastrozole)","Femara (Letrozole)","Nutropin (Somatropin)","Genotropin (Somatropin)"],"phase":"phase_3","status":"active","brandName":"Aromatase Inhibitor and Growth Hormone","genericName":"Aromatase Inhibitor and Growth Hormone","companyName":"Nemours Children's Clinic","companyId":"nemours-children-s-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy inhibits aromatase to reduce estrogen production while supplementing growth hormone to promote linear growth in pediatric patients. Used for Growth hormone deficiency in children, Short stature in pediatric patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}